Use of surrogate endpoints: A practical necessity in lipid-altering and antiatherosclerosis drug development

American Journal of Cardiology

Volumn 87, Issue 4 SUPPL. 1, 2001, Pages 35-41

  Orloff, David G ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE MARKER; DRUG APPROVAL; DRUG EFFICACY; DRUG LABELING; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035895666     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01423-0     Document Type: Article

References (31)

1. The challenge of regulating development and approval of drugs with pleiotropic action in cardiovascular disease
2. Hyperlipidemia: Diagnostic and therapeutic perspectives
3. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies
4. Stability and instability: Two faces of coronary atherosclerosis
5. Cholesterol reduction in cardiovascular disease
6. Inflammatory markers of coronary risk
7. Atherosclerosis: An inflammatory disease
8. Lipoproteins and atherogenesis
9. Putting low-density lipoproteins at center stage in atherogenesis
10. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: Lipid and non-lipid factors
11. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease
12. Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: Clinical aspects
13. Atherogenicity of triglyceride-rich lipoproteins
14. Hypertriglyceridemia, atherogenic dyslipidemia, and metabolic syndrome
15. Hypertriglyceridemia: Changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease
16. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment
17. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease
18. CETP and atherosclerosis
19. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
20. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy
21. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease
22. Relation between baseline and on-treatment lipid parameters and first acute major coronary event in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
23. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women
24. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
25. Postprandial lipoprotein metabolism and atherosclerosis
26. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography
27. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events
28. Role of intravascular ultrasound in the evaluation of mechanisms of coronary interventions and restenosis
29. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification
30. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])
31. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: A randomized controlled trial